SEARCH

SEARCH BY CITATION

References

  • 1
    Noel RA, Braun DK, Patterson RE, Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective, cohort study. Diabetes Care2009; 32: 834838.
  • 2
    Girman CJ, Kou TD, Cai B, Alexander CM, O’Neill EA, Williams-Herman DE et al.Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab2010; 12: 766771.
  • 3
    Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care2010; 33: 23492354.
  • 4
    Blomgren KB, Sundstrom A, Steineck G, Wiholm BE. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care2002; 25: 298302.
  • 5
    Torgerson JS, Lindroos AK, Näslund I, Peltonen M. Gallstones, gallbladder disease, and pancreatitis: cross-sectional and 2-year data from the Swedish Obese Subjects (SOS) and SOS Reference Studies. Am J Gastroenterol2003; 98: 10321041.
  • 6
    Suazo-Barahona J, Carmona-Sanchez R, Robles-Diaz G, Milke-Garcia P, Vargas-Vorackova F, Uscanga-Dominguez L et al.Obesity: a risk factor for severe acute biliary and alcoholic pancreatitis. Am J Gastroenterol1998; 93: 13241328.
  • 7
    Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC.Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia2010; 53: 2126.
  • 8
    Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care2010; 33: 453455.
  • 9
    Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?Diabetologia2010; 53: 16.
  • 10
    Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R et al.Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes2009; 58: 16041615.
  • 11
    Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P et al.Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia2010; 53: 153159.
  • 12
    Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes2009; 58: 21482161.
  • 13
    US Food and Drug Administration. Summary Basis of Approval for BYETTA (NDA21-773): Pharmacology Review. 2005. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_pharmr.PDF Last accessed 26 August 2010.
  • 14
    Bruce S, MacConell LA, Brown C, Han J, Nicewarner D, Braun DK et al.Safety and tolerability of exenatide BID in patients with type 2 diabetes: integrated analysis of 3834 patients from 11 comparator-controlled clinical trials. Diabetes2009; 58: A155A156.
  • 15
    Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al.Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin2008; 24: 275286.
  • 16
    Shen L, Han J, Yushmonova I, Bruce S, Porter L. Cardiovascular safety of exenatide BID: an integrated-analysis from long- term controlled clinical trials in subjects with type 2 diabetes. Diabetes2009; 58: A96A97.
  • 17
    Bloomgren G, Dore D, Patterson R, Noel R, Braun D, Seeger J.Incidence rates for acute pancreatitis in patients with type 2 diabetes initiating exenatide BID compared to initiating other antidiabetic agents. Diabetes2009; 58: A41.
  • 18
    Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K et al.Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of non-uniform effect. Am J Epidemiol2006; 163: 262270.
  • 19
    D’Agostino R. Tutorial on biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med1998; 17: 22652281.
  • 20
    Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika1983; 70: 4155.
  • 21
    Ohman EM. Risk stratification and therapeutic decision making in acute coronary syndromes. J Am Med Assoc2000; 284: 876878.
  • 22
    Peterson ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR.Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis2007; 45: 908915.
  • 23
    Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care2007; 45: S103S107.
  • 24
    Yadav D, Rohtashav D. How accurate are ICD-9 codes for acute (AP) and chronic (CP) pancreatitis?—A large VA hospital experience. Pancreas2006; 33: 508.
  • 25
    Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Secular trends in incidence and 30-day case fatality of acute pancreatitis in North Jutland County, Denmark: a register-based study from 1981–2000. Scand J Gastroenterol2002; 37: 14611465.
  • 26
    Eland IA, Alvarez CH, Stricker BHC, Garcia-Rodriguez LA. The risk of acute pancreatitis associated with acid-supressing drugs. Br J Clin Pharmacol2000; 49: 473478.
  • 27
    Dore D, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. Pharmacoepidemiol Drug Saf2011; 20: 209213.
  • 28
    Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin2009; 25: 10191027.
  • 29
    McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol2000; 53: 12481257.
  • 30
    Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet2008; 371: 143152.